World Journal of Surgical Oncology最新文献

{"title":"Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040.","authors":"Feifan Chu, Lumin Chen, Qing Guan, Zujie Chen, Qiwei Ji, Yuning Ma, Jinzhong Ji, Mingxin Sun, Tingyang Huang, Haihan Song, Hao Zhou, Xiuquan Lin, Yichun Zheng","doi":"10.1186/s12957-025-03733-1","DOIUrl":"10.1186/s12957-025-03733-1","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is the second most common cancer among men worldwide. This study uses data from the 2021 Global Burden of Disease (GBD) study to estimate the global burden of prostate cancer from 1990 to 2021.</p><p><strong>Methods: </strong>We analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of prostate cancer globally from 1990 to 2021. Based on the Sociodemographic Index (SDI), we used the estimated annual percentage change (EAPC) and Age-Period-Cohort model to compare the burden of disease across different age groups and regions with varying levels of development. Finally, we used the Bayesian Age-Period-Cohort model to predict the trend of changes in the disease burden of prostate cancer by 2040.</p><p><strong>Results: </strong>In 2021, the global age-standardized incidence rate (ASIR) of prostate cancer was 15.37 per 100,000, an increase from 13.69 per 100,000 in 1990. However, the age-standardized mortality rate (5.26 per 100,000) and DALY rate (95.94 per 100,000) decreased significantly compared to 1990. The burden of prostate cancer increased with age, but overall, the burden across all age groups was lower in 2021 than in 1990. The only exception was the incidence rate among individuals under 75 in 2021. High-income regions such as North America and Australia exhibited the highest burden in terms of ASIR, though there has been some reduction in recent years. Conversely, the burden of mortality and DALYs was highest in regions such as sub-Saharan Africa, West Africa, and the Caribbean, where rates have continued to rise. Correlation analysis between SDI and the EAPC of the disease burden showed a negative correlation between EAPC of prostate cancer mortality and DALYs with SDI. The APC analysis showed that in 2021, the ASIR of prostate cancer in high SDI regions was still significantly higher across all age groups compared to other regions. In regions with middle SDI and above, the age-standardized mortality rate and DALY rate decreased over time or across birth cohorts, with a faster decline in areas with higher SDI. By 2040, it is projected that the global ASIR of prostate cancer will reverse its current trend and increase, while the age-standardized mortality rate and DALY rate will continue to decline, and the counts of incidence, mortality, and DALYs will keep rising.</p><p><strong>Conclusion: </strong>Although the global mortality rate and DALY rate for prostate cancer show a decreasing trend, the number of new cases, deaths, and DALYs continues to rise due to global population growth and the aging population, and the disease burden remains significant. Furthermore, there are substantial geographic disparities in the disease burden of prostate cancer. Therefore, targeted programs should be implemented to strengthen prostate cancer diagnosis and treatment in these specific regions.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"98"},"PeriodicalIF":2.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma.","authors":"Xing Lv, Rong-Hua Zhu, Gui-Bao Ji, Jian Li, Wen-Qiang Wang, Jin-Lin Wang, Bin-Yong Liang, Er-Lei Zhang, Zhi-Yong Huang","doi":"10.1186/s12957-025-03743-z","DOIUrl":"10.1186/s12957-025-03743-z","url":null,"abstract":"<p><strong>Background: </strong>Intraoperative intraperitoneal lavage with lobaplatin is widely used in the treatment of colorectal and gastric cancers. This study aimed to explore the efficacy of lobaplatin lavage in patients with ruptured hepatocellular carcinoma (HCC) administered radical hepatectomy.</p><p><strong>Methods: </strong>Ruptured HCC patients who underwent hepatectomy between September 2007 and March 2022 were divided into the distilled water lavage and lobaplatin lavage groups. Survival curves for RFS and OS were generated by the Kaplan-Meier method and compared by the log-rank test using Propensity Score Matching (PSM). Cox regression analysis was conducted to identify independent prognostic factors of RFS and OS.</p><p><strong>Results: </strong>This study included 201 patients, with 114 cases (89.1%) in the distilled water lavage group and 55 cases (75.3%) in the lobaplatin lavage group experiencing recurrence, and 95 (74.2%) and 44 (60.3%) patients died in the distilled water lavage and lobaplatin lavage groups, respectively during the follow-up period. After PSM, 1-, 2-, 3-year RFS rates were 38.6%, 21.1%, 10.5% and 57.9%, 40.4%, 26.3% in the distilled water lavage and lobaplatin lavage groups, respectively (P = 0.001). 1-, 2-, 3-year OS rates were 56.1%, 40.4%, 33.3% and 89.5%, 63.2%, 43.9% in the distilled water lavage and lobaplatin lavage groups, respectively (P = 0.001). Multivariable Cox regression indicated that lobaplatin lavage may improve RFS (HR = 0.524, 95% CI: 0.354-0.775;P = 0.001) and OS (HR = 0.524, 95% CI: 0.350-0.783;P = 0.002).</p><p><strong>Conclusions: </strong>Intraoperative lobaplatin lavage improves RFS and OS in patients with ruptured HCC after hepatectomy.</p><p><strong>Trial registration: </strong>TJ-IRB202403002, 2024-04-26, retrospectively registered.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"96"},"PeriodicalIF":2.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-based body composition analysis to study the effect of visceral obesity on postoperative complications in ovarian cancer: implications for young patients.","authors":"Shuyue Su, Tianle Weng, Jingying Bai, Chunchun Fang, Rongrong Shao, Mengxiao Sun, Haote Jiang, Yuyang Zhang","doi":"10.1186/s12957-025-03740-2","DOIUrl":"10.1186/s12957-025-03740-2","url":null,"abstract":"<p><strong>Purpose: </strong>Ovarian cancer is characterized by high morbidity and mortality, with surgery remaining the primary treatment modality. The occurrence of postoperative complications significantly impacts patient prognosis and quality of life. As cancer increasingly affects younger individuals, it is crucial to consider age-related differences. Meanwhile, epidemiology suggests a high prevalence of obesity among females. This study aims to evaluate the effect of visceral obesity (VO), diagnosed using computed tomography (CT)-based body composition analysis, on postoperative complications.</p><p><strong>Methods: </strong>A total of 309 patients operated between 2017 and 2022 were included in this study. Patients were stratified into two age groups: ≤65 years (younger group) and > 65 years (older group). The receiver operating characteristic (ROC) curve was employed to determine the threshold value for VO. Univariate and multivariate analyses were conducted to identify risk factors associated with postoperative complications.</p><p><strong>Results: </strong>According to the cut-off value, the incidence of postoperative complications was significantly higher in younger patients with VO compared to the non-VO group (56% vs. 36%, p < 0.01), whereas no difference was observed in older age groups. VO (OR = 1.980, p = 0.031), total protein < 65 g/L (OR = 3.704, p = 0.045), primary debulking surgery (PDS) (OR = 0.369, p = 0.026), duration of surgery (OR = 1.004, p = 0.006) and intraoperative bleeding volume (OR = 1.003, p < 0.01) were identified as independent predictors of postoperative complications in the younger age group. International Federation of Gynecology and Obstetrics (FIGO) stage for III or IV (OR = 4.00, p = 0.029) remained as the only independent predictor for the older age group.</p><p><strong>Conclusions: </strong>In young ovarian cancer patients, VO may serve as a predictor for postoperative complications, and appropriate preventive measures may be beneficial in reducing the incidence of postoperative complications.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"95"},"PeriodicalIF":2.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases at an Australian centre.","authors":"Raymond Hayler, Natalie Domingos, Amir Ashrafizadeh, Ruwanthi Wijayawardana, Nima Ahmadi, Winston Liauw, David Morris","doi":"10.1186/s12957-025-03749-7","DOIUrl":"10.1186/s12957-025-03749-7","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer is a major cause of cancer mortality, with poorer prognosis in the presence of peritoneal metastases as low as 2.8-9 months. Systemic therapy has a limited role. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. This study evaluates survival of patients with gastric cancer and peritoneal metastases (GCPM) undergoing CRS and HIPEC at an Australian centre.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on a prospectively collected database of patients who underwent CRS and HIPEC for GCPM from January 2009 to December 2023. Data included demographics, perioperative factors, histopathology and survival.</p><p><strong>Results: </strong>Twenty-four patients were identified, with median postoperative overall survival of 11.7 months (95% CI 8.6-34.2 months). Most patients had poorly differentiated adenocarcinoma (n = 23, 96%), with 14 (58%) exhibiting signet cell pathology. 62% (n = 15) received preoperative chemotherapy. Median PCI was 5, with a CC score of 0 in 96% of patients (n = 23). Clavien-Dindo III/IV morbidity was noted in 8 patients (33%) with no perioperative mortality. No survival differences were found between those with signet cell pathology and those without (10.6 vs. 11.7 months, p = 0.83), nor between those receiving preoperative chemotherapy and those who did not (11.7 vs. 10.6 months, p = 0.60). Age, sex, PCI, CC and tumour markers demonstrated correlations with survival in linear regression, but no individual factor significantly influenced outcomes.</p><p><strong>Conclusion: </strong>CRS and HIPEC for low volume GCPM should be considered in select patients.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"93"},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The correlation of tertiary lymphoid structures with tumor spread through air spaces and prognosis in lung adenocarcinoma: focusing on pathological spatial features.","authors":"Yun Ding, Mengting Yu, Mengli Xue, Wenkang Zong, Yangyun Huang, Jie Ren, Tianxing Guo, Daqiang Sun, Xiaojie Pan","doi":"10.1186/s12957-025-03751-z","DOIUrl":"10.1186/s12957-025-03751-z","url":null,"abstract":"<p><p>Lung adenocarcinoma (LADC) exhibits high spatial heterogeneity, with distinct spatial variations in pathological features. The distribution of tertiary lymphoid structures (TLS) in LADC is uneven, and different TLS characteristics play unique roles. To investigate the correlation between TLS features and other pathological characteristics, particularly tumor spread through air spaces (STAS), we analyzed TLS and other pathological features on whole-slide images stained with HE and CD20/CD23. Additionally, the 14-Gene assay was used to assess prognostic risk. Among 388 enrolled LADC patients, 226 (58.2%) were TLS-positive. TLS showed a negative correlation with various adverse pathological features, with boundary-area TLS demonstrating the strongest correlation with STAS quantity (r= -0.324, P < 0.001). Multivariate Cox analysis identified boundary-area TLS as an independent prognostic factor for recurrence-free survival (HR = 0.856, 95% CI = 0.759-0.966, P = 0.026), while mature TLS was an independent factor for overall survival (HR = 0.841, 95% CI = 0.717-0.988, P = 0.035). High-density TLS at the tumor boundary was associated with low-risk stratification by the 14-Gene assay (P = 0.013). This study highlights the negative correlation between TLS and STAS, especially in boundary areas, and emphasizes the impact of tumor microenvironment spatial characteristics on clinical outcomes. Assessment of spatial heterogeneity in LADC facilitates precise risk stratification for patients.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"94"},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives.","authors":"Zhiyao Chen, Yunbin Ma, Jianan Chen","doi":"10.1186/s12957-025-03752-y","DOIUrl":"10.1186/s12957-025-03752-y","url":null,"abstract":"<p><p>Gastric adenocarcinoma (GAC) remains a significant global public health challenge, characterized by high incidence and mortality rates. Progress in tumor immunology has introduced immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways, demonstrating substantial potential in GAC therapy. Clinical research indicates that ICIs, particularly when combined with chemotherapy or targeted therapies, significantly enhance treatment efficacy in advanced GAC and specific molecular subtypes, including microsatellite instability-high (MSI-H) and human epidermal growth factor receptor 2 (HER2)-positive patients. However, immunotherapy is also associated with a range of immune-related adverse events (irAEs), necessitating effective management strategies to ensure treatment safety and maintain patients' quality of life. Future studies should focus on identifying new therapeutic targets, optimizing patient selection, and developing personalized treatment approaches to further improve the efficacy and safety of immunotherapy in GAC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"92"},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"cfDNA hydroxymethylcytosine profiling for detection metastasis and recurrence of Esophageal Squamous Cell Carcinoma.","authors":"Subinuer Kuerban, Hangyu Chen, Long Chen, Lei Zhang, Xuehui Li, Baixin Zhen, Hong Xiao, Yingzhu Chen, Haitao Zhou, Zhen Liang, Guobing Xu, Yicun Tao, Jian Lin, Xiaozheng Kang","doi":"10.1186/s12957-025-03747-9","DOIUrl":"10.1186/s12957-025-03747-9","url":null,"abstract":"<p><strong>Background: </strong>A blood-based approach to monitor metastasis and recurrence of esophageal squamous cell carcinoma (ESCC) remains undeveloped. This study aimed to establish a dependable model utilizing cfDNA 5-hydroxymethylcytosines (5hmC) signatures to detect these conditions in ESCC.</p><p><strong>Methods: </strong>The 5hmC-Seal technique was employed to generate comprehensive 5hmC profiles from the plasma cell-free DNA (cfDNA) of 122 ESCC patients, classified into 72 with metastasis, 50 without metastasis, 30 with recurrence, and 92 without recurrence. Initial steps involved identifying distinct hydroxymethylation signatures linked to metastasis and recurrence. Machine learning algorithms were then utilized to construct predictive models.</p><p><strong>Results: </strong>The study confirmed that 5hmC-based markers are predictive of metastasis and recurrence among ESCC patients. The analysis of 14 5hmC biomarkers revealed a sensitivity of 88.90% and a specificity of 84.00% (AUC = 0.922) in differentiating patients with ESCC metastasis from those without in the validation cohort. Similarly, 11 5hmC biomarkers showed a sensitivity of 93.30% and a specificity of 89.10% (AUC = 0.936) in identifying recurrent versus non-recurrent ESCC cases. Additionally, a wp-score for metastasis and recurrence, derived from the 5hmC marker, prognosticated patient outcomes.</p><p><strong>Conclusions: </strong>The findings indicate that 5hmC markers from cfDNA serve as effective epigenetic indicators for the non-invasive detection of ESCC metastasis and recurrence.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"90"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing aesthetic outcomes of different incision types for nipple-sparing mastectomy followed by radiation therapy in prepectoral direct-to-implant breast reconstruction: a retrospective study.","authors":"Jae Hoon Jeong, Ha Eun Park, Eun-Kyu Kim, Chan Yeong Heo, Chongsoo Park","doi":"10.1186/s12957-025-03730-4","DOIUrl":"10.1186/s12957-025-03730-4","url":null,"abstract":"<p><strong>Background: </strong>This study analyzes the aesthetic outcomes associated with inframammary fold (IMF) incisions compared to radial incisions, with or without a periareolar component (referred to as periareolar/radial, PR), considering nipple-sparing mastectomy (NSM) followed by prepectoral direct-to-implant (DTI) reconstruction and subsequent post-mastectomy radiotherapy (PMRT). We assessed changes in breast and nipple symmetry, nipple-to-IMF distance, and nipple Y-axis coefficients to understand how different incisions influence post-radiation aesthetic outcomes.</p><p><strong>Methods: </strong>Forty patients who underwent NSM and prepectoral DTI reconstruction followed by PMRT between September 2019 and December 2022 in a single institution were included. Patients were divided into PR incision (n = 9) and IMF incision (n = 31) groups, with the latter further separated into IMF 1 group (surgeries from 2019 to 2021, n = 13) and IMF 2 group (surgeries in 2022, n = 18). Pre- and postoperative (6-18 months after surgery) analyses of body measurements and medical photographs were conducted using the Seoul Breast Esthetic Scoring Tool (S-BEST) software, developed by same institution, to calculate breast symmetry scores, nipple-to-IMF distance, and nipple Y-axis coefficients. Statistical analyses assessed differences between groups.</p><p><strong>Results: </strong>All groups showed decreased breast symmetry scores postoperatively (PR group: -1.111, IMF 1 group: -0.539, IMF 2 group: -0.389) and increased nipple-to-IMF distance (PR group: 0-0.2 cm, IMF 1 group: 0.2-0.5 cm, IMF 2 group: 0.3-0.4 cm). The changes in nipple y-axis coefficients were minimal across all groups. And the PR group received a lower average radiation dose (47.64 ± 5.2 Gy) than IMF 1 group (54.45 ± 5.28 Gy) and IMF 2 group (54.07 ± 4.79 Gy). Statistical analysis indicated no significant differences across the groups (p > 0.05, Kruskal-Wallis test).</p><p><strong>Conclusions: </strong>While IMF and PR incisions yielded similar aesthetic outcomes post-radiation, IMF incisions showed trends toward better symmetry, especially at higher radiation doses. These findings support the IMF incision as a favorable choice in NSM with DTI reconstruction followed by PMRT, though patient anatomy and preferences remain critical for surgical planning.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"91"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total laparoscopy-assisted total gastrectomy with Da Vinci robotic system conducted by robotic enhanced neurocomputing joint intelligence gastrointestinal surgery hub (RENJI-GISH): a preliminary clinical study and case report.","authors":"Zihang Liu, Jiayi Gu, Yeqian Zhang, Long Bai, Yujing Guan, Bo Ni, Haoyu Zhang, Muerzhate Aimaiti, Puhua Zhang, Xiaoyao Shen, Shuchang Wang, Ben Yue, Xiang Xia, Zizhen Zhang","doi":"10.1186/s12957-025-03735-z","DOIUrl":"10.1186/s12957-025-03735-z","url":null,"abstract":"<p><strong>Background: </strong>On August 7, 2024, the inaugural total laparoscopy-assisted total gastrectomy with the Da Vinci robotic system was performed in the department of gastrointestinal surgery of Renji Hospital, Shanghai Jiaotong University School of Medicine. The procedure, conducted by RENJI-GISH, employed the use of a Da Vinci robot system in conjunction with the Vision Pro and SonoScape medical electronic endoscopy system. This phenomenon has not been documented in the field of gastric cancer surgery The objective of this study is to investigate the safety, feasibility, and surgical effect of the first total laparoscopy-assisted total gastrectomy with the Da Vinci robotic system, conducted by the Robotic Enhanced Neurocomputing Joint Intelligence Gastrointestinal Surgery Hub (RENJI-GISH).</p><p><strong>Case presentation: </strong>A 71-year-old male patient was admitted to the hospital with a six-month history of nausea and vomiting. A gastric malignant tumor was identified through gastroscopic examination. The patient was diagnosed with cardiac adenocarcinoma by gastroscopy and pathology, and there were clear indications for surgical intervention, though no contraindications were identified. On August 7, 2024, the patient underwent a robot-assisted total laparoscopic gastrectomy under general anesthesia. During the surgical procedure, the Vision Pro and the electronic endoscopy system played a pivotal role in accurately identifying the location of the gastric lesions, confirming the resection margin of the tumor, and ensuring the safety of the anastomosis. The intraoperative blood loss was 20 ml, and the operative time was 180 min. On the third postoperative day, the patient passed flatus and was transitioned to a liquid diet on the fourth postoperative day. The patient was discharged on the seventh postoperative day, having not experienced any complications. The postoperative pathology report indicated that the lymph node dissection was complete (0/32), and no evidence of malignancy was identified in the upper and lower resection margins.</p><p><strong>Conclusions: </strong>This case study illustrates the safety and feasibility of total laparoscopy-assisted total gastrectomy with the Da Vinci robotic system, performed by the robotic enhanced neurocomputing joint intelligence gastrointestinal surgery hub (RENJI-GISH). Further investigation and experimentation are necessary to fully elucidate the potential of this approach.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"86"},"PeriodicalIF":2.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative adjuvant therapy for stage IA-IIA cervical adenocarcinoma (FIGO 2018) with one intermediate-risk factor: a multicentre retrospective cohort study of 63,926 cases.","authors":"Jiaxin Fu, Cong Liang, Lixin Sun, Hongwei Zhao, Zhumei Cui, Jinghe Lang, Chunlin Chen, Ping Liu","doi":"10.1186/s12957-025-03739-9","DOIUrl":"10.1186/s12957-025-03739-9","url":null,"abstract":"<p><strong>Objective: </strong>To compare the 5-year oncological outcomes of different adjuvant treatment modalities in patients with FIGO 2018 stage IA-IIA cervical adenocarcinoma who underwent open radical hysterectomy and one intermediate-risk pathological factor.</p><p><strong>Methods: </strong>Based on the Four C database (between 2004 and 2018,n=63,926), patients with FIGO 2018 stage IA-IIA cervical adenocarcinoma and only one intermediate-risk pathological factor underwent open extensive hysterectomy. All patients were divided into three groups, namely, the simple surgery group (radical hysterectomy, RH), postoperative adjuvant chemotherapy group (radical hysterectomy and chemotherapy, RH + CT), and postoperative adjuvant chemoradiotherapy group (radical hysterectomy and radiotherapy/concurrent chemoradiotherapy, RH + RT/CCRT). The 5-year OS and DFS rates were compared among the three groups.</p><p><strong>Results: </strong>Of the 219 cervical adenocarcinoma patients with only one intermediate-risk pathological factor, 50 patients had RH; 54 patients had RH + CT; and 115 patients had RH + RT/CCRT. There were no significant differences in 5-year OS and 5-year DFS rates among the three groups (RH vs. RH + CT: 92.7% vs. 90.3%, P = 0.749; 88.5% vs. 85.1%, P = 0.680, RH vs. RH + RT/CCRT: 90.7% vs. 82.3%, P = 0.484; 84.4% vs. 90.1%, P = 0.494, RH + CT vs. RH + RT/CCRT: 89.9% vs. 90.6%, P = 0.815; 90.5% vs. 90.8%, P = 0.905).</p><p><strong>Conclusion: </strong>Postoperative adjuvant chemotherapy or chemoradiotherapy did not significantly improve the outcomes of FIGO 2018 IA-IIA cervical adenocarcinoma patients with only one intermediate risk factor.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"87"},"PeriodicalIF":2.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}